G-BA

AcronymDefinition
G-BAGemeinsamer Bundesausschuss (Germany: common federal committee)
References in periodicals archive ?
Fycompa was re-submitted in May 2014 to the G-BA for additional benefit assessment due to a change in the assessment process, but in November of the same year the G-BA determined once again that no additional benefit could be proven.
Eisai temporarily suspended Fycompa from distribution in Germany following the previous negative G-BA ruling in March 2013 and established a patient access program for continued supply of Fycompa free of charge to German pharmacies through individual import to ensure that people with epilepsy continue to receive treatment with Fycompa, while the G-BA considers the resubmission.
This assessment by the G-BA affirms the additional benefit of Halaven, and differs from the preliminary assessment by Germany's IQWiG (Institute for Quality and Efficiency in Health Care)(2) published in February in 2012.